- Continued growth and new record sales of 261.6 million CHF
- EBIT margin rises to 19.3% while EBITDA margin remains stable at 27.3%
- Increase in net income to 41.8 million CHF despite adverse foreign exchange effects
- Rise in dividend by 10% from 2.50 to 2.75 CHF proposed
- Confirmed growth forecast
Bubendorf/Basel, March 16, 2018 – Bachem (SIX: BANB), the market leader in peptide chemistry and a company that focuses on quality and innovation, has reported a solid result for the first half of fiscal 2017 with a further improvement in the second half of the year. Expectations were again high for the 2017 fiscal year. Sales came to 261.6 million CHF (2016: 236.5 million CHF, +10.6% in CHF). Bachem lifted its operating result (EBIT) by 12.3% to 50.6 million CHF and the EBIT margin widened once again, improving to 19.3% (prior year: 19.1%). Operating profit before depreciation and amortization (EBITDA) came to 71.5 million CHF (previous year: 64.8 million CHF). This equates to an EBITDA margin of 27.3%. In contrast to the positive contribution in the prior year, currency translation effects had a significantly negative impact on net income for the year under review. Overall, exchange rate movements resulted in a consolidated exchange rate loss of 1.8 million CHF (previous year: gain of 1.2 million CHF). Posting net income of 41.8 million CHF, the company slightly exceeded the previous year’s result despite these significant negative effects. Operating net income before currency translation effects, by contrast, rose significantly.